It is believed that Mounjaros tendency to cause electrolyte imbalances, dehydration, blood sugar fluctuations, stress, and fatigue may increase a persons risk
Adding glucagon-receptor activity is the conceptual leap, since glucagon signalling contributes energy expenditure rather than only appetite and glycaemic effects
In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it
This constraint has hindered structureactivity relationship studies and rational pharmacologic development
Hydrate aggressively
Judge Marstons August 15, 2025 ruling clarified: Clinical diagnosis based solely on symptoms is not sufficient You must have objective diagnostic testing Specifically: gastric emptying scan (4-hour scintigraphy study) Alternative tests: gastric emptying breath test or wireless motility capsule (SmartPill, though discontinued) Why this matters: Many patients were told they had gastroparesis based only on symptoms Without objective testing, defendants will challenge the diagnosis Court ruled that symptom-based diagnosis isnt reliable enough Need scientific proof of delayed gastric emptying What if you have symptoms but no formal testing
.png&w=828&q=100)
